Patents by Inventor David V. Serreze

David V. Serreze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT
    Publication number: 20230389531
    Abstract: The present disclosure relates to genetically modified non-obese diabetic (NOD) mice deficient in murine class I MHC molecules, class II molecules, or both class I and class II MHC molecules. The MHC knockout transgenic mice provided herein are useful, for example, for developing therapies for diabetes.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Applicant: The Jackson Laboratory
    Inventors: David V. Serreze, Jeremy J. Racine
  • Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
    Patent number: 11712026
    Abstract: The present disclosure relates to genetically modified non-obese diabetic (NOD) mice deficient in murine class I MHC molecules, class II molecules, or both class I and class II MHC molecules. The MHC knockout transgenic mice provided herein are useful, for example, for developing therapies for diabetes.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: August 1, 2023
    Assignee: The Jackson Laboratory
    Inventors: David V. Serreze, Jeremy J. Racine
  • Antigens targeted by pathogenic AI4 T cells in type 1 diabetes and uses thereof
    Patent number: 8318670
    Abstract: Provided are oligopeptide antigens to AI4-like T cells, and mouse proteins comprising those antigens. The oligopeptide antigens comprise the amino acid sequence XX(I/D/F/L)ENY(I/L)(E/W/Y)(L/M) or VMLENYTHL. Additionally provided are methods for treating a mammal having or at risk for type 1 diabetes using these antigens, or compounds which reduce or eliminate expression of these antigens. Kits comprising these antigens, and methods for determining whether a mammal is at risk for or has type 1 diabetes are also provided.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: November 27, 2012
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Jackson Laboratory
    Inventors: Teresa P. DiLorenzo, Scott M. Lieberman, David V. Serreze
  • Antigens Targeted by Pathogenic Al4 T Cells in Type 1 Diabetes and Uses Thereof
    Publication number: 20100009923
    Abstract: Provided are oligopeptide antigens to A14-like T cells, and mouse proteins comprising those antigens. The oligopeptide antigens comprise the amino acid sequence XX(I/D/F/L)ENY(I/L)(E/W/Y)(L/M) or VMLENYTHL. Additionally provided are methods for treating a mammal having or at risk for type 1 diabetes using these antigens, or compounds which reduce or eliminate expression of these antigens. Kits comprising these antigens, and methods for determining whether a mammal is at risk for or has type 1 diabetes are also provided.
    Type: Application
    Filed: July 26, 2005
    Publication date: January 14, 2010
    Inventors: Teresa P. DiLorenzo, Scott M. Lieberman, David V. Serreze
  • Antigens Targeted by Pathogenic T Cells in Type 1 Diabetes and Uses Thereof
    Publication number: 20090137485
    Abstract: Provided are polypeptides that are capable of binding a human HLA-A2 MHC class I molecule. Kits comprising these polypeptides in a container are also provided. Further provided are methods for determining whether a mammal is at risk for or has type 1 diabetes. Additionally provided are methods of preventing a CD8+ T cell that is cytotoxic to pancreatic islet ?-cells from destroying a ?-cell. Methods of treating a mammal that is at risk for type 1 diabetes are also provided, as are methods of treating a mammal that has type 1 diabetes.
    Type: Application
    Filed: March 9, 2006
    Publication date: May 28, 2009
    Inventors: Teresa P. Dilorenzo, Toshiyuki Takaki, David V. Serreze, Michele Marron